Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Director | June 09, 2026 | June 11, 2026 |
| BioPlus Acquisition Corp.BIOS · Entity 112459 | Director | December 02, 2021 | December 03, 2021 |
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Director | May 05, 2020 | May 28, 2020 |
| Epiphany Technology Acquisition Corp.EPHY · Entity 123266 | Director | September 16, 2022 | October 04, 2022 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,193 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 1,505 · Balance 15,193 F1: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.
BioPlus Acquisition Corp.
Report date December 02, 2021 · Filed December 03, 2021
This filing explicitly reported no securities owned.
CHINOOK THERAPEUTICS, INC.
Report date May 05, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2030-05-04 | Direct | 30,000 |
Reported balance
After 2020-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant.
Epiphany Technology Acquisition Corp.
Report date September 16, 2022 · Filed October 04, 2022
This filing explicitly reported no securities owned.
NEUROCRINE BIOSCIENCES INC
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,860 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Gift · Disposed 1,000 · Balance 14,860 F1: This transaction represents a gift/charitable contribution effective September 2, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents a gift/charitable contribution effective September 2, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Neon Therapeutics, Inc.
Report date May 06, 2020 · Filed May 07, 2020
Section 16 reporting ended · disclosed 2020-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 1
1 source rowRow 1 · 2020-05-06 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-06 · Disposition to issuer · Disposed 14,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-06 · Disposition to issuer · Disposed 18,500 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-05-06 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted.
F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").
F3: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 01:39 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001079462-26-000008 · wk-form4_1788485992.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,860 F1 · kind: This transaction represents a gift/charitable contribution effective September 2, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 21:47 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,505 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000064 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,193 F1 · shares: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 10,000 | $0.00 Strike: $79.79 | $0.00 |
DisclosureSEC source: 0001079462-26-000006 · wk-form4_1781041231.xml · derivative · entry 9 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option was granted May 22, 2019 and vested in 12 equal monthly installments beginning June 22, 2019. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $53.64 | $0.00 |
DisclosureSEC source: 0001079462-26-000006 · wk-form4_1781041231.xml · derivative · entry 8 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,843 | $167.31 | $308,357.49 |
DisclosureSEC source: 0001079462-26-000006 · wk-form4_1781041231.xml · nonDerivative · entry 7 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,860 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.11 to $167.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,829 | $166.56 | $970,859.00 |
DisclosureSEC source: 0001079462-26-000006 · wk-form4_1781041231.xml · nonDerivative · entry 6 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,703 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $166.11 to $167.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 6,896 | $165.79 | $1,143,305.77 |
DisclosureSEC source: 0001079462-26-000006 · wk-form4_1781041231.xml · nonDerivative · entry 5 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,532 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.11 to $166.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,549 | $164.44 | $419,156.03 |
DisclosureSEC source: 0001079462-26-000006 · wk-form4_1781041231.xml · nonDerivative · entry 4 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,428 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.11 to $164.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 7,883 | $163.81 | $1,291,290.58 |
DisclosureSEC source: 0001079462-26-000006 · wk-form4_1781041231.xml · nonDerivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,977 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.11 to $164.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 10,000 | $79.79 | $797,900.00 |
DisclosureSEC source: 0001079462-26-000006 · wk-form4_1781041231.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $53.64 | $804,600.00 |
DisclosureSEC source: 0001079462-26-000006 · wk-form4_1781041231.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2026 Filed May 29, 2026 22:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestriced Stock Unit · Derivative | 2,567 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001079462-26-000004 · wk-form4_1780092183.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,567 Underlying: Common Stock · 2,567 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 27, 2027. F2 · derivative.expiration_date: The RSUs will vest in full on May 27, 2027. Read SEC document |
| May 21, 2026 Filed May 21, 2026 23:24 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 3,318 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001079462-26-000002 · wk-form4_1779405893.xml · derivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. Read SEC document |
| May 21, 2026 Filed May 21, 2026 23:24 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 3,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001079462-26-000002 · wk-form4_1779405893.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000169 · wk-form4_1756939653.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,542 F1 · kind: This transaction represents a gift/charitable contribution effective September 2, 2025. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:42 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 2,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-017759 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,688 Read SEC document |
| May 22, 2025 Filed May 22, 2025 21:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,869 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000130 · wk-form4_1747949168.xml · derivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,869 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested. F3 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested. Read SEC document |
| May 22, 2025 Filed May 22, 2025 21:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,869 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000130 · wk-form4_1747949168.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 3,318 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000130 · wk-form4_1747949168.xml · derivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,318 Underlying: Common Stock · 3,318 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 21, 2026. F2 · derivative.expiration_date: The RSUs will vest in full on May 21, 2026. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 20:09 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 8,760 | $150.02 | $1,314,141.91 |
DisclosureSEC source: 0001127602-25-008861 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,318 Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:49 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 13,831 | $116.69 | $1,613,922.79 |
DisclosureSEC source: 0000914475-25-000071 · wk-form4_1739576962.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,673 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.79 to $118.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 04, 2024 Filed Nov 8, 2024 00:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000218 · wk-form4_1731026551.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,504 F1 · kind: This transaction represents a gift/charitable contribution effective November 4, 2024. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:20 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-019240 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,078 Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $47.89 | $0.00 |
DisclosureSEC source: 0000914475-24-000160 · wk-form4_1717101501.xml · derivative · entry 6 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options will expire ten years from the date of grant on May 20, 2026. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 25,000 | $0.00 Strike: $42.76 | $0.00 |
DisclosureSEC source: 0000914475-24-000160 · wk-form4_1717101501.xml · derivative · entry 5 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,000 | $133.47 | $2,002,009.50 |
DisclosureSEC source: 0000914475-24-000160 · wk-form4_1717101501.xml · nonDerivative · entry 4 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,504 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2024. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.00 to $136.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $47.89 | $718,350.00 |
DisclosureSEC source: 0000914475-24-000160 · wk-form4_1717101501.xml · nonDerivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 25,000 | $133.46 | $3,336,555.00 |
DisclosureSEC source: 0000914475-24-000160 · wk-form4_1717101501.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,504 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2024. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.22 to $136.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 25,000 | $42.76 | $1,069,000.00 |
DisclosureSEC source: 0000914475-24-000160 · wk-form4_1717101501.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2024 Filed May 23, 2024 22:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 2,869 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000152 · wk-form4_1716503359.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,869 Underlying: Common Stock · 2,869 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 22, 2025. F2 · derivative.expiration_date: The RSUs will vest in full on May 22, 2025. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 4,199 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000127 · wk-form4_1716324649.xml · derivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 4,199 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000127 · wk-form4_1716324649.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:10 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GiftCommon Stock | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056033 · doc4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,305 F1 · shares: This transaction represents a gift/charitable contribution effective November 16, 2023. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 960 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019548 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,738 Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:24 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 4,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031131 · doc4.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,199 Underlying: Common Stock · 4,199 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units will vest in full on May 17, 2024. F2 · derivative.expiration_date: The Restricted Stock Units will vest in full on May 17, 2024. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $12.98 Strike: $12.98 | $194,700.00 |
DisclosureSEC source: 0001209191-23-002054 · doc4.xml · derivative · entry 6 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted May 22, 2014 and vested monthly over one year. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $12.71 Strike: $12.71 | $190,650.00 |
DisclosureSEC source: 0001209191-23-002054 · doc4.xml · derivative · entry 5 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted May 23, 2013 and vested monthly over one year. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,000 | $118.85 | $1,782,751.50 |
DisclosureSEC source: 0001209191-23-002054 · doc4.xml · nonDerivative · entry 4 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,055 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $117.75 to $119.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $12.98 | $194,700.00 |
DisclosureSEC source: 0001209191-23-002054 · doc4.xml · nonDerivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,000 | $118.87 | $1,782,976.50 |
DisclosureSEC source: 0001209191-23-002054 · doc4.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,055 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $117.75 to $119.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $12.71 | $190,650.00 |
DisclosureSEC source: 0001209191-23-002054 · doc4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2022 Filed Jan 27, 2023 23:28 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 695 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002502 · form5.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,778 Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017811 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,473 Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 9,724 | $0.00 Strike: $84.95 | $0.00 |
DisclosureSEC source: 0001209191-22-031003 · doc4.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,724 Underlying: Common Stock · 9,724 shares Expires 2032-05-18 F1 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 18, 2022. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 22:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $6.66 Strike: $6.66 | $99,900.00 |
DisclosureSEC source: 0001209191-22-005109 · doc4.xml · derivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted May 23, 2012 and vested monthly over one year. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 22:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,000 | $74.43 | $1,116,378.00 |
DisclosureSEC source: 0001209191-22-005109 · doc4.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,055 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $73.21 to $75.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 22:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $6.66 | $99,900.00 |
DisclosureSEC source: 0001209191-22-005109 · doc4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 23:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070071 · doc4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,055 F1 · shares: This transaction represents gift/charitable donations effective December 14, 2021. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:33 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021349 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,103 Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 8,833 | $0.00 Strike: $92.35 | $0.00 |
DisclosureSEC source: 0001209191-21-034389 · doc4.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,833 Underlying: Common Stock · 8,833 shares Expires 2031-05-19 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.